Antisoma backs pipeline to get through ASA404 disaster
This article was originally published in Scrip
Antisoma is determined to bounce back from the recent catastrophic disappointment with its lead anticancer candidate ASA404 and is hoping clinical data expected over the coming year from other product candidates will turn its fortunes around.
You may also be interested in...
As financial turmoil broke out around the world in the wake of the vote for Brexit, UK pharma majors GlaxoSmithKline and AstraZeneca saw their stock rise. There's an uncertain outlook for the broader life sciences sector.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.